Alpha Cognition Set for Growth with Upcoming BEACON Study Results
AI Prediction of Alpha Cognition Inc. Common Stock (ACOG)
Alpha Cognition Inc. (ACOG) is positioned for potential growth with its FDA-approved Alzheimer's drug, ZUNVEYL, and upcoming catalysts including international approvals and real-world study results.
Alpha Cognition Inc., a biopharmaceutical company, has made significant strides with its lead product ZUNVEYL, an FDA-approved treatment for mild to moderate Alzheimer's disease. The drug is currently launched in the U.S. and targets a substantial segment of the Alzheimer's market, particularly in long-term care facilities. In addition to its U.S. operations, the company is anticipating additional country approvals in Asia in 2026, which could provide substantial market expansion opportunities. Alpha Cognition is also generating post-market data from the BEACON study expected in Q4 2026, aimed at bolstering the drug's real-world efficacy and adoption. The convergence of these factors presents a promising outlook for the company's valuation and stock performance in the near term.
ACOG Report Information
Prediction Date2026-03-18
Close @ Prediction$5.76
Mkt Cap126m
IPO Date2021-06-09
AI-derived Information
Recent News for ACOG
- Mar 13, 1:46 pm — Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 (Business Wire)
- Mar 10, 8:30 am — Alpha Cognition to Present New Clinical on ZUNVEYL (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences (Business Wire)
- Feb 25, 8:30 am — Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study (Business Wire)
- Feb 18, 8:30 am — Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens (Business Wire)
- Jan 7, 4:30 pm — Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution (Business Wire)
- Dec 5, 9:40 am — Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? (Zacks)
- Dec 1, 5:51 pm — Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners (Business Wire)
- Nov 19, 9:41 am — Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? (Zacks)
- Nov 14, 6:40 pm — Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
- Nov 14, 9:46 am — Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025 (Newsfile)
- Nov 13, 4:00 pm — Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
- Nov 12, 7:54 am — MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for ACOG
No NDAPR events found.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest